TORONTO, Oct. 29, 2020 /PRNewswire-PRWeb/ -- Immunosequencing, the science of profiling T- and B-cell receptors, has broad utility across the clinical development spectrum. Adaptive Biotechnologies' quantitative immunoSEQ Technology has the ability to answer early, preclinical questions such as those around drug candidate selection, dosing and effective drug combinations. As a therapeutic pipeline matures to the clinical trial stage, the immunoSEQ Assay can also help confirm drug safety and efficacy, establish biomarker endpoints, optimize patient selection, predict response to therapy and monitor for adverse events.
This webinar will use real-world data to demonstrate how immunosequencing can be leveraged at various points in the drug development and clinical trial process to improve the development of new therapies.
For more information or to register for this event, visit From Bench to Biomarker: Applications of the immunoSEQ Assay Across the Clinical Development Pipeline.
The immunoSEQ Assay is For Research Use Only. Not for use in diagnostic procedures.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.